These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11540313)

  • 41. Fluoride treatment of postmenopausal osteoporosis: age, renal function, and other clinical factors in the osteogenic response.
    Murray TM; Harrison JE; Bayley TA; Josse RG; Sturtridge WC; Chow R; Budden F; Laurier L; Pritzker KP; Kandel R
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S27-35. PubMed ID: 2339633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Phenytoin and fluoride act in concert to stimulate bone formation and to increase bone volume in adult male rats.
    Ohta T; Wergedal JE; Matsuyama T; Baylink DJ; Lau KH
    Calcif Tissue Int; 1995 May; 56(5):390-7. PubMed ID: 7621347
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Effects of the combined raloxifene-sodium fluoride therapy on bone mass and bone turnover in women with postmenopausal osteoporosis].
    Celi M; Letizia C; Ragno A; Minisola S; D'Erasmo E; Mazzuoli GF
    Minerva Med; 2002 Dec; 93(6):471-8. PubMed ID: 12515970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of osteoporosis with human parathyroid peptide and observations on effect of sodium fluoride.
    Reeve J; Davies UM; Hesp R; McNally E; Katz D
    BMJ; 1990 Aug; 301(6747):314-8. PubMed ID: 2393738
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monofluorophosphate physiology: the effects of fluoride on bone.
    Baylink DJ; Duane PB; Farley SM; Farley JR
    Caries Res; 1983; 17 Suppl 1():56-76. PubMed ID: 6357456
    [No Abstract]   [Full Text] [Related]  

  • 46. [Conclusive evaluation of osteoporosis therapy with fluorides].
    Hesch RD; Rittinghaus EF
    Internist (Berl); 1991 Dec; 32(12):708-20. PubMed ID: 1783513
    [No Abstract]   [Full Text] [Related]  

  • 47. Long-term fluoride and calcium therapy of postmenopausal osteoporosis.
    Lie H; Malde K; Sorteberg K; Hasvold O; Ekren T; Malm OJ
    J Oslo City Hosp; 1982 Dec; 32(12):147-54. PubMed ID: 7153813
    [No Abstract]   [Full Text] [Related]  

  • 48. Fluoride bioavailability from immediate-release sodium fluoride with calcium carbonate compared with slow-release sodium fluoride with calcium citrate.
    Sakhaee K; Pak CY
    Bone Miner; 1991 Aug; 14(2):131-6. PubMed ID: 1912761
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparative effects of sodium fluoride and hormonal replacement therapy on bone metabolism in osteoporotic women with high fracture risk. Results of monitoring for 2 years].
    Pouillès JM; Trémollières F; Ribot C
    Rev Rhum Mal Osteoartic; 1992 Feb; 59(2):103-13. PubMed ID: 1604221
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sodium fluoride lacks mitogenic activity for fetal human bone cells in vitro.
    Kopp JB; Robey PG
    J Bone Miner Res; 1990 Mar; 5 Suppl 1():S137-41. PubMed ID: 2339623
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of sodium fluoride on trabecular architecture.
    Aaron JE; de Vernejoul MC; Kanis JA
    Bone; 1991; 12(5):307-10. PubMed ID: 1782099
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The effect of fluoride on bone histology in postmenopausal osteoporosis depends on adequate fluoride absorption and retention.
    Budden FH; Bayley TA; Harrison JE; Josse RG; Murray TM; Sturtridge WC; Kandel R; Vieth R; Strauss AL; Goodwin S
    J Bone Miner Res; 1988 Apr; 3(2):127-32. PubMed ID: 3213607
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Fluorosis following the long-term treatment of osteoporosis with sodium fluoride].
    Meseg S; Matzkowski H; Hasert V
    Z Gesamte Inn Med; 1986 Jan; 41(1):22-4. PubMed ID: 3082082
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Should we use fluoride to treat osteoporosis? A review.
    Kanis JA; Meunier PJ
    Q J Med; 1984; 53(210):145-64. PubMed ID: 6379725
    [No Abstract]   [Full Text] [Related]  

  • 55. Sustained-release sodium fluoride in the management of established postmenopausal osteoporosis.
    Pak CY; Sakhaee K; Rubin CD; Zerwekh JE
    Am J Med Sci; 1997 Jan; 313(1):23-32. PubMed ID: 9001163
    [No Abstract]   [Full Text] [Related]  

  • 56. Strontium ranelate in osteoporosis.
    Reginster JY
    Curr Pharm Des; 2002; 8(21):1907-16. PubMed ID: 12171530
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characterization of a rapidly responding animal model for fluoride-stimulated bone formation.
    Lundy MW; Farley JR; Baylink DJ
    Bone; 1986; 7(4):289-93. PubMed ID: 3768209
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Streptozotocin Aggravated Osteopathology and Insulin Induced Osteogenesis Through Co-treatment with Fluoride.
    Yang C; Zhang M; Li Y; Wang Y; Mao W; Gao Y; Xu H
    Biol Trace Elem Res; 2015 Dec; 168(2):453-61. PubMed ID: 26018496
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Comparative study of the in vitro effects of calcitonin, NaF and ipriflavone in cell culture].
    Bucsi L; Ashton BA
    Magy Traumatol Ortop Kezseb Plasztikai Seb; 1994; 37(3):257-60. PubMed ID: 7920911
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The effect of tamoxifen and fluoride on bone mineral density, biomechanical properties and blood lipids in ovariectomized rats.
    Czerny B; Pawlik A; Juzyszyn Z; Myśliwiec Z
    Basic Clin Pharmacol Toxicol; 2004 Oct; 95(4):162-5. PubMed ID: 15504151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.